Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

被引：0
|
作者：
Helen Jenkins
Richard Jenkins
Alain Patat
机构：
[1] Takeda Development Centre Europe Ltd,
[2] Biotrial S.A.,undefined
来源：
Clinical Drug Investigation | 2017年 / 37卷
关键词：
Clarithromycin; Single Oral Dose; Gastric Acid Secretion; Multiple Oral Dose; Potent CYP3A4 Inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：311 / 316
页数：5
相关论文
共 50 条
  • [1] Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study
    Jenkins, Helen
    Jenkins, Richard
    Patat, Alain
    CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 311 - 316
  • [2] Effects of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of a single oral dose of tamsulosin
    Troost, J.
    Tatami, S.
    Tsuda, Y.
    Mattheus, M.
    Mehlburger, L.
    Michel, M. C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 305 - 305
  • [3] Pharmacokinetics of oral viaminate in healthy Chinese subjects: an open-label, sequential, single-dose, food-effect, and multiple-dose study
    Li, Lingjun
    Shen, Yue
    Ma, Pengcheng
    Tao, Lei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11639 - 11644
  • [4] Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
    Alberto Papi
    Andrea F. D. Di Stefano
    Milko Radicioni
    Advances in Therapy, 2021, 38 : 468 - 478
  • [5] Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
    Papi, Alberto
    Di Stefano, Andrea F. D.
    Radicioni, Milko
    ADVANCES IN THERAPY, 2021, 38 (01) : 468 - 478
  • [6] Exploring the pharmacokinetics and tolerability of cyclooxygenase inhibitor ampiroxicam: a phase I study on single and multiple oral doses
    Zhao, Pengfei
    Qi, Ying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Pharmacokinetics of Icosapent Ethyl: An Open-Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects
    Yuan, Fei
    Li, Hui
    Yang, Mengjie
    Chen, Weili
    Chen, Hanjing
    Xu, Hongrong
    Li, Jing
    Sheng, Lei
    Liu, Chao
    Li, Ye
    Li, Huan
    Li, Xuening
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (01): : 6 - 13
  • [8] Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug alprazolam
    Drabant, Sandor
    Toth, Maria
    Bereczki, Andrea
    Bajnogel, Judit
    Tomlo, Judit
    Klebovich, Imre
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (07) : 587 - 588
  • [9] Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam
    Sándor Drabant
    Mária Tóth
    Andrea Bereczki
    Judit Bajnógel
    Judit Tömlö
    Imre Klebovich
    European Journal of Clinical Pharmacology, 2006, 62 : 587 - 588
  • [10] Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
    Kim, Seokuee
    Lee, Jongtae
    Shin, Donghoon
    Lim, Kyoung Soo
    Kim, Yon Su
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1723 - 1731
12345